title: Clopidogrel reduces platelet-leucocyte aggregation, monocyte activation and RANTES secretion in type 2 diabetes mellitus.
authors.forename: S A
authors.initials: SA
authors.lastname: Harding
authors.forename: J
authors.initials: J
authors.lastname: Sarma
authors.forename: J N
authors.initials: JN
authors.lastname: Din
authors.forename: P M
authors.initials: PM
authors.lastname: Maciocia
authors.forename: D E
authors.initials: DE
authors.lastname: Newby
authors.forename: K A A
authors.initials: KA
authors.lastname: Fox
mesh_terms: D018946:Chemokine CCL5 / Q000378:metabolism*; D000077144:Clopidogrel; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000187:drug effects*; D008213:Lymphocyte Activation / Q000187:drug effects; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: D018946:Chemokine CCL5; D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine